Skip to Main Content

Everyone loves a winner, but who are they? Let us help you figure it out. Each Friday, we will provide a quick rundown of individuals or companies that accomplished something worth noting. But to be fair, we will also point out those who, well, had a rough time. And if you have a nomination, send us a note. We would not want anyone to feel left out, even the losers.


Scott Gottlieb: After a two-hour Senate confirmation hearing the other day, the policy wonk, industry consultant, physician, and venture capitalist looks like he will become the next commissioner of the Food and Drug Administration. Gottlieb may harbor notions about loosening some approaches FDA takes to reviewing or assessing medicines. And his ties to industry may be too close for comfort for many people. But he deftly handled a wide array of questions with aplomb and did a good job of avoiding missteps. Moreover, he is comparatively moderate when stacked against the other two names that were floated by the Trump administration. Both espoused radical views, which might have seemed like a deliberate tactic by a White House that was, otherwise, organized and politically calculating.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!